Overview
Ripped Injectable (RAD-140 + S-23) is an advanced cutting supplement, available for purchase at Iron Mountain Labz. This product combines two prominent selective androgen receptor modulators (SARMs), RAD-140 and S-23. Each of these compounds has been the subject of extensive research for their potential effects on muscle and tissue systems in laboratory settings.
RAD-140, also known as Testolone, is known for its anabolic properties, selectively targeting muscle tissue. On the other hand, S-23 has garnered attention for its strong androgenic effects, making it an intriguing option for those focused on cutting cycles. Together, these compounds create a powerful injectable supplement aimed at optimizing your research outcomes.
Key Features
- Combines RAD-140 and S-23 for synergistic effects
- Designed specifically for laboratory research
- Injectable form for fast results
- Research-backed formulation
- Ideal for cutting cycles
Specifications
| Product | Details |
|---|---|
| Formulation | RAD-140 + S-23 Injectable |
| Volume | 10 mL |
| Usage | For laboratory research only |
FAQ
What is Ripped Injectable used for?
Ripped Injectable is primarily used for laboratory research on muscle and tissue systems, particularly during cutting cycles.
How do I use Ripped Injectable?
This product is intended for research purposes and should be used in accordance with your laboratory protocols.
Is Ripped Injectable safe for human consumption?
No, Ripped Injectable is not approved for human consumption and is only intended for laboratory research use.
Shop Ripped Injectable (RAD-140 + S-23) now to enhance your research capabilities. Experience the difference in your cutting studies with this premium product from Iron Mountain Labz.
Related Products
- Shred Injectable (T3 Liothyronine Sodium + SR-9011 + Yohimbine)
- L-Carnitine Injections for Sale
- Cardarine GW-501516 Capsules for Sale
Browse more in Cutting Supplements.
Always read the label and use products as directed. Consult a qualified professional where appropriate.




